Lisata Therapeutics (LSTA) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $3.9 million.
- Lisata Therapeutics' Accumulated Expenses fell 449.82% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 449.82%. This contributed to the annual value of $4.3 million for FY2024, which is 383.79% up from last year.
- According to the latest figures from Q3 2025, Lisata Therapeutics' Accumulated Expenses is $3.9 million, which was down 449.82% from $3.5 million recorded in Q2 2025.
- Over the past 5 years, Lisata Therapeutics' Accumulated Expenses peaked at $4.3 million during Q4 2024, and registered a low of $3.2 million during Q1 2025.
- Its 3-year average for Accumulated Expenses is $3.9 million, with a median of $3.9 million in 2023.
- As far as peak fluctuations go, Lisata Therapeutics' Accumulated Expenses soared by 824.61% in 2024, and later crashed by 2125.31% in 2025.
- Lisata Therapeutics' Accumulated Expenses (Quarter) stood at $4.2 million in 2023, then rose by 3.84% to $4.3 million in 2024, then dropped by 8.78% to $3.9 million in 2025.
- Its last three reported values are $3.9 million in Q3 2025, $3.5 million for Q2 2025, and $3.2 million during Q1 2025.